靶点针对疾病信息18(本栏目收费,不能显示细节,电话13136136841)
靶点针对疾病信息
标题
内容
TARGETID
T25265
TARGNAME
Enhancer of zeste homolog 2 (EZH2)
INDICATI
Approved Brain cancer [ICD-11: 2A00]
INDICATI
Approved Diffuse large B-cell lymphoma [ICD-11: 2A81]
INDICATI
Approved Peritoneal cancer [ICD-11: 2C51]
INDICATI
Approved Synovial sarcoma [ICD-11: 2B5A]
INDICATI
Phase 2 Lung cancer [ICD-11: 2C25]
INDICATI
Phase 2 Mature B-cell lymphoma [ICD-11: 2A85]
INDICATI
Phase 2 Mature T-cell lymphoma [ICD-11: 2A90]
INDICATI
Phase 2 Ureteral cancer [ICD-11: 2C92]
INDICATI
Phase 1/2 B-cell lymphoma [ICD-11: 2A86]
INDICATI
Phase 1/2 Malignant haematopoietic neoplasm [ICD-11: 2B33]
INDICATI
Phase 1/2 Prostate cancer [ICD-11: 2C82]
INDICATI
Investigative Breast cancer [ICD-11: 2C60-2C6Y]
免责声明:以上所展示的信息由企业自行提供,内容的真实性、准确性和合法性由发布企业负责,医药网对此不承担任何责任。
相关链接:医药研究数据| 医药资料| SDA药品评审中心| 中医网| 中药处方系统| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究  客服热线:0575-83552251 / 13754370441  QQ客服:药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证:浙B2-20220931 互联网药品信息服务资格证书编号:(浙)-经营性2023-0215 浙公网安备:330683240604819103159
 医药代理商群1:药药网药品采购交流医药代理商群2:药药网药品采购交流2医药代理商群3:药药网药品采购交流3